@article{3103659,
    title = "KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer",
    author = "Porta, C. and Bamias, A. and Danesh, F.R. and Dębska-Ślizień, A. and Gallieni, M. and Gertz, M.A. and Kielstein, J.T. and Tesarova, P. and Wong, G. and Cheung, M. and Wheeler, D.C. and Winkelmayer, W.C. and Małyszko, J. and Abu-Alfa, A.K. and Amer, H. and Beutel, G. and Chapman, J. and Chen, X. and Chudek, J. and Cosmai, L. and Danesi, R. and De Stefano, F. and Iseki, K. and Jaimes, E.A. and Jhaveri, K.D. and Jurczyszyn, A. and Kazancioğlu, R. and Kitchlu, A. and Kollmannsberger, C. and Lahoti, A. and Li, Y. and Macía, M. and Matsubara, T. and Mitropoulos, D. and Noiri, E. and Perazella, M.A. and Ronco, P. and Rosner, M.H. and Soler Romeo, M.J. and Sprangers, B. and Stadler, W.M. and Stevens, P.E. and ladimír Tesař and Torres da Costa e Silva, V. and Vesole, D.H. and Vijayan, A. and Viklický, O. and Workeneh, B.T. and Yanagita, M. and Zakharova, E.",
    journal = "Kidney International",
    year = "2020",
    volume = "98",
    number = "5",
    pages = "1108-1119",
    publisher = "Elsevier B.V.",
    issn = "0085-2538, 1523-1755",
    doi = "10.1016/j.kint.2020.06.046",
    keywords = "acetylcysteine;  angiotensin receptor antagonist;  antianemic agent;  antineoplastic agent;  axitinib;  bicarbonate;  cabozantinib;  capecitabine;  cisplatin;  contrast medium;  crizotinib;  cytotoxic T lymphocyte antigen 4 inhibitor;  dabrafenib;  dipeptidyl carboxypeptidase inhibitor;  gemcitabine;  ifosfamide;  immune checkpoint inhibitor;  immunological antineoplastic agent;  interferon;  iron;  lenvatinib;  methotrexate;  oxaliplatin;  pamidronic acid;  pazopanib;  pemetrexed;  programmed death 1 receptor blocking agent;  protein tyrosine kinase inhibitor;  sorafenib;  sunitinib;  unclassified drug;  vasculotropin inhibitor;  vemurafenib;  zoledronic acid, acute kidney failure;  anemia;  bladder cancer;  breast cancer;  cancer incidence;  cancer patient;  cancer risk;  cancer screening;  chemoprophylaxis;  chimeric antigen receptor T-cell immunotherapy;  chronic kidney failure;  colorectal cancer;  computer assisted tomography;  Conference Paper;  contrast induced nephropathy;  cytopenia;  cytoreductive surgery;  diarrhea;  disease association;  dose response;  drug efficacy;  drug mechanism;  drug megadose;  drug withdrawal;  echography;  electrolyte disturbance;  Fanconi renotubular syndrome;  follow up;  glomerulonephritis;  hematopoietic stem cell transplantation;  hemodialysis patient;  human;  hypertension;  interdisciplinary research;  iron therapy;  kidney biopsy;  kidney cancer;  kidney cyst;  kidney disease;  kidney function;  kidney injury;  kidney tubule disorder;  liver cancer;  liver cell carcinoma;  magnesium wasting;  medical decision making;  metastasis;  nephrectomy;  nephritis;  nephrogenic diabetes insipidus;  nephrotic syndrome;  nephrotoxicity;  pancreas cancer;  partial nephrectomy;  pathophysiology;  perioperative period;  postoperative period;  prevalence;  priority journal;  professional knowledge;  prostate cancer;  proteinuria;  radiation nephropathy;  renal cell carcinoma;  renal replacement therapy;  sodium wasting;  solid malignant neoplasm;  surgical risk;  tongue cancer;  treatment outcome;  urinary tract cancer;  urinary tract disease;  uterine cervix cancer;  practice guideline",
    abstract = "The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues in the setting of malignancy can worsen patient outcomes and diminish the adequacy of anticancer treatments. In addition, the oncology treatment landscape is changing rapidly, and data on tolerability of novel therapies in patients with CKD are often lacking. Caring for oncology patients has become more specialized and interdisciplinary, currently requiring collaboration among specialists in nephrology, medical oncology, critical care, clinical pharmacology/pharmacy, and palliative care, in addition to surgeons and urologists. To identify key management issues in nephrology relevant to patients with malignancy, KDIGO (Kidney Disease: Improving Global Outcomes) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology in December 2018. This report covers issues related to kidney impairment and solid organ malignancies as well as management and treatment of kidney cancer. Knowledge gaps, areas of controversy, and research priorities are described. © 2020 Kidney Disease:Improving Global Outcomes (KDIGO)"
}